Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocugen, Inc. (OCGN)
THE ANGEL–(BUSINESS WIRE) – Glancy Prongay & Murray LLP (“GPM”) is reminding investors of the upcoming August 16, 2021 deadline to file lead plaintiffs in the class action on behalf of investors who have bought or otherwise acquired Ocugen, Inc. (“Ocugen “Or the” Company “) (NASDAQ: OCGN) securities between February 2, 2021 and June 10, 2021, inclusive (the” Class Period “).
If you have suffered a loss on your Ocugen investments or would like to inquire about whether you would like to claim under U.S. securities laws to recover your loss, you can find your contact information at https://www.glancylaw.com/cases/ ocugen-inc. to transfer /. You can also contact Charles H. Linehan of GPM at 310-201-9150, toll free at 888-773-9224, or email [email protected] to learn more about your rights.
Ocugen is a biopharmaceutical company. Under an agreement with Bharat Biotech, Ocugen has exclusive rights to develop, manufacture and commercialize COVAXIN, a vaccine candidate for COVID-19.
On June 10, 2021, Ocugen announced that it would file a Biologics License Application (“BLA”) for COVAXIN, which has a longer approval process than an Emergency Authorization (“EUA”) application, and that an additional one is expected conduct clinical trial attempt to support the submission.
As a result of this news, the company’s share price fell $ 2.62 per share, or 28%, to close at $ 6.69 per share on June 10, 2021, hurting investors.
The lawsuit filed alleges that, during the class action period, defendants made materially false and / or misleading statements and failed to disclose material adverse facts about the company’s business, operations and prospects. In particular, Defendants have failed to disclose to investors that: (1) the information presented to the FDA was insufficient to support an EEA; (2) Ocugen would not file an emergency clearance with the FDA; and (3) as a result, Defendants’ statements about its business, operations and prospects were materially false and misleading and / or were inadequate at all relevant times.
Follow us for updates on LinkedIn, Twitter or Facebook.
If you have purchased or otherwise acquired Ocugen securities during the class action period, you may request the court to appoint you as the lead plaintiff in this alleged class action no later than August 16, 2021. To become a member of the class action, you do not need to take any action at this point; You can hire a lawyer of your choice or you can take no action and remain an absent member of the class action. If you would like to learn more about this class action, or if you have any questions about this announcement or your rights or interests in relation to the pending class action, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, toll free at 888-773-9224, email [email protected], or visit our website at www.glancylaw.com. For inquiries by e-mail, please include your postal address, telephone number and the number of shares purchased.
This press release may be viewed as a solicitation in some jurisdictions subject to applicable laws and ethical rules.